Karyopharm Therapeutics Inc. last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $33.4 million (-11.9% year over year) and diluted EPS of -$2.32. It usually reports 8–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Oct 7, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Oct 8, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
33
-11.9%
|
-67
-79.9%
|
-2.32
+46.3%
|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
35
+16.8%
|
-22
+4.6%
|
-1.24
+55.2%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
34
+11.6%
|
-102
-232.0%
|
-5,716.76
-57.8%
|
|
Oct 8, 2025
8 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
44
+13.6%
|
-33
-3.3%
|
-3.82
+0.8%
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
38
-11.4%
|
-37
-256.6%
|
-4.32
-45.5%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
30
-9.4%
|
-23
+37.2%
|
-2.77
+42.9%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
31
-9.5%
|
-31
+26.4%
|
-3,623.92
-2759.3%
|
|
Nov 5, 2024
36 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
39
+7.7%
|
-32
+7.1%
|
-3.85
-1183.3%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KPTI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newton, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1503802
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.